From the Journals

Consensus guidelines address inpatient diabetes technology


 

Most detailed guidance addresses logistics and data management

Most of the strong recommendations regarding logistics are aimed at nursing staff, including receiving training in use of CGM and AID systems, confirming patient capacity, inspection of devices, and understanding when to administer a point-of-care glucose test.

Again, the panel calls for more data and for hospitals to develop policies and protocols for ensuring safe CGM and AID systems use, and when to avoid use.

Finally, they make one strong clinical recommendation regarding data management: “Healthcare providers should develop a set of core data elements and definitions for CGM data for inclusion in common data models and the electronic health record.”

That’s followed by a long list of relevant recommendations for research in the area, and for hospitals to integrate CGM and AID system data into their EHR systems.

This last area has proven particularly challenging, Galindo said. “Right now we do four point-of-care glucoses a day, and that goes right into the EHR, but with CGM it’s much more than that. How do we get all those data into the EHR and interpret it? Many steps need to be taken into consideration.”

Studies are being conducted in order to fulfill requirements for FDA approval of inpatient CGM use, he said, with data on implementation and inpatient AID system use to follow.

“More data will be available, triggered by the COVID-19 pandemic. However, the use of technology in the hospital goes beyond COVID-19,” he said

Galindo has reported receiving unrestricted research support to Emory for investigator-initiated studies from Novo Nordisk and Dexcom, and consulting fees from Abbott Diabetes Care, Sanofi, Novo Nordisk, Eli Lilly, and Valeritas. He is partially supported by research grants from the NIH/NIDDK.

This article first appeared on Medscape.com.

Pages

Recommended Reading

Black diabetics lose limbs at triple the rate of others. Here’s how health care leaders are starting to act.
Journal of Clinical Outcomes Management
FDA OKs new ‘artificial pancreas’ Medtronic 770G
Journal of Clinical Outcomes Management
Pesco-Mediterranean diet, fasting ‘ideal’ to reduce CVD risk
Journal of Clinical Outcomes Management
Exercise cuts diabetes death risk by a third in two studies
Journal of Clinical Outcomes Management
Higher glycemic time in range may benefit T2D patients
Journal of Clinical Outcomes Management
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
Journal of Clinical Outcomes Management
Dapagliflozin’s CKD performance sends heart failure messages
Journal of Clinical Outcomes Management
Recall widens for diabetes drug metformin
Journal of Clinical Outcomes Management
Diabetic neuropathic pain linked to brain bioenergic anomalies
Journal of Clinical Outcomes Management
‘Modest’ benefit for post-MI T2D glucose monitoring
Journal of Clinical Outcomes Management